Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

ONTOLOGY REPORT - ANNOTATIONS


Term:EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
go back to main search page
Accession:CHEBI:50750 term browser browse the term
Definition:A topoisomerase inhibitor that inhibits DNA topoisomerase (ATP-hydrolysing), EC 5.99.1.3 (also known as topoisomerase II and as DNA gyrase), which catalyses ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands.
Synonyms:related_synonym: DNA gyrase inhibitor;   DNA gyrase inhibitors;   DNA topoisomerase (ATP-hydrolysing) inhibitor;   DNA topoisomerase (ATP-hydrolysing) inhibitors;   DNA topoisomerase II inhibitor;   DNA topoisomerase II inhibitors;   EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitors;   EC 5.99.1.3 inhibitor;   EC 5.99.1.3 inhibitors;   inhibitor of type II topoisomerase;   inhibitors of type II topoisomerase;   topoisomerase II inhibitor;   topoisomerase II inhibitors;   type II DNA topoisomerase inhibitor;   type II DNA topoisomerase inhibitors
 alt_id: CHEBI:132229;   CHEBI:50234


show annotations for term's descendants       view all columns           Sort by:
 

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 0
    role 0
      biological role 0
        biochemical role 0
          enzyme inhibitor 0
            EC 5.* (isomerase) inhibitor 0
              EC 5.99.* (other isomerases) inhibitor 0
                EC 5.99.1.* (miscellaneous isomerase) inhibitor 0
                  topoisomerase inhibitor 0
                    EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor 0
                      (R)-temafloxacin + 0
                      (S)-temafloxacin + 0
                      4'-epidoxorubicin 0
                      4,4'-propane-1,3-diyldipiperazine-2,6-dione 0
                      ICRF-193 0
                      TOP-53 0
                      aclacinomycin A 0
                      aclacinomycin A zwitterion 0
                      amsacrine 0
                      betulinic acid + 0
                      celastrol 0
                      ciprofloxacin + 0
                      ciprofloxacin dihydrochloride 0
                      ciprofloxacin hydrochloride (anhydrous) + 0
                      ciprofloxacin hydrochloride hydrate 0
                      dihydrobetulinic acid 0
                      ellagic acid + 0
                      fisetin + 0
                      fleroxacin 0
                      flumequine 0
                      gatifloxacin + 0
                      genistein + 0
                      kaempferol 3-O-(5-O-acetyl-alpha-D-apiofuranosyl)-7-O-alpha-L-rhamnopyranoside 0
                      kaempferol 3-O-alpha-L-arabinopyranosyl-7-O-alpha-L-rhamnopyranoside 0
                      kaempferol 3-O-beta-D-apiofuranosyl-7-O-alpha-L-rhamnopyranoside 0
                      kaempferol 3-O-beta-D-glucopyranosyl-7-O-alpha-L-rhamnopyranoside 0
                      lucanthone + 0
                      maleimide + 0
                      manoalide 0
                      methyl brevifolincarboxylate 0
                      nepalensinol D 0
                      nepalensinol E 0
                      nepalensinol F 0
                      novobiocin 0
                      procyanidin B4 + 0
                      temafloxacin 0
                      teniposide 0
                      wedelolactone 0
paths to the root

NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.